UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

ACG Clinical Guideline: Ulcerative Colitis in Adults

The American journal of gastroenterology, 2019-03, Vol.114 (3), p.384-413

2019

Volltextzugriff (PDF)

Transforming Gastroenterology Care With Telemedicine

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.958-963

Siegel, Corey A., MD, MS

2017

Volltextzugriff (PDF)

A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease

The American journal of gastroenterology, 2021-10, Vol.116 (10), p.2014-2025

2021

Volltextzugriff (PDF)

The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium

The American journal of gastroenterology, 2016-08, Vol.111 (8), p.1147-1155

2016

Volltextzugriff (PDF)

Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis

Gastroenterology (New York, N.Y. 1943), 2015-02, Vol.148 (2), p.344-354.e5

2015

Volltextzugriff (PDF)

Do inflammatory bowel disease therapies cause cancer?

Inflammatory bowel diseases, 2013-05, Vol.19 (6), p.1306-1321

2013

Volltextzugriff (PDF)

Management of IBD Patients Who Are Unwilling or Unable to Receive Infusion Therapy During the COVID-19 Pandemic

Inflammatory bowel diseases, 2020-11, Vol.26 (11), p.e137-e137

2020

Volltextzugriff (PDF)

Evaluating the Impact of Cost on the Treatment Algorithm for Chronic Idiopathic Constipation: Cost-Effectiveness Analysis

The American journal of gastroenterology, 2021-10, Vol.116 (10), p.2118-2127

2021

Volltextzugriff (PDF)

Are We Ready to Include Prognostic Factors in Inflammatory Bowel Disease Trials?

Current pharmaceutical design, 2019-01, Vol.25 (1), p.64-68

2019

Volltextzugriff (PDF)

Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti–Tumor Necrosis Factor Therapy for Crohn’s Disease: A Meta-analysis of Placebo-controlled Trials

Clinical gastroenterology and hepatology, 2015-12, Vol.13 (13), p.2233-2240.e2

2015

Volltextzugriff (PDF)

Medical Marijuana for Digestive Disorders: High Time to Prescribe?

The American journal of gastroenterology, 2015-02, Vol.110 (2), p.208-214

2015

Volltextzugriff (PDF)

Patients with IBD Want to Talk About Sleep and Treatments for Insomnia with Their Gastroenterologist

Digestive diseases and sciences, 2023-06, Vol.68 (6), p.2291-2302

2023

Volltextzugriff (PDF)

Hyperbaric oxygen therapy is well tolerated and effective for ulcerative colitis patients hospitalized for moderate-severe flares: a phase 2A pilot multi-center, randomized, double-blind, sham-controlled trial

The American journal of gastroenterology, 2018-10, Vol.113 (10), p.1516-1523

2018

Volltextzugriff (PDF)

Fostering Collaboration Through Creation of an IBD Learning Health System

The American journal of gastroenterology, 2017-03, Vol.112 (3), p.406-408

2017

Volltextzugriff (PDF)

Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care?

Gastroenterology (New York, N.Y. 1943), 2018-03, Vol.154 (4), p.1201-1202

2018

Volltextzugriff (PDF)

Refocusing IBD Patient Management: Personalized, Proactive, and Patient-Centered Care

The American journal of gastroenterology, 2018-10, Vol.113 (10), p.1440-1443

Siegel, Corey A

2018

Volltextzugriff (PDF)

Optimization of Drug Safety Profile in Inflammatory Bowel Disease Through a Personalized Approach

Current drug targets, 2018-01, Vol.19 (7), p.740-747

2018

Volltextzugriff (PDF)

Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options

Gut, 2012-03, Vol.61 (3), p.459-465

Siegel, Corey A

2012

Volltextzugriff (PDF)

The Risk of Malignancy Associated with the Use of Biological Agents in Patients with Inflammatory Bowel Disease

Gastroenterology clinics of North America, 2014-09, Vol.43 (3), p.525-541

2014

Volltextzugriff (PDF)

Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population

Clinical gastroenterology and hepatology, 2012-09, Vol.10 (9), p.1002-1007

2012

Volltextzugriff (PDF)

Appropriateness of Testing for Anti–Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results

Clinical gastroenterology and hepatology, 2016-09, Vol.14 (9), p.1302-1309

2016

Volltextzugriff (PDF)

Placing Value on Telemedicine for Inflammatory Bowel Disease

The American journal of gastroenterology, 2019-03, Vol.114 (3), p.382-383

Siegel, Corey A

2019

Volltextzugriff (PDF)

People with IBD evidence more microarousals during sleep architecture assessments

BMJ open gastroenterology, 2023-12, Vol.10 (1), p.e001249

2023

Volltextzugriff (PDF)

Prognosticating the Course of Inflammatory Bowel Disease

Gastrointestinal endoscopy clinics of North America, 2019-07, Vol.29 (3), p.395-404

2019

Volltextzugriff (PDF)

Implementing Quality Measures for Inflammatory Bowel Disease

Current gastroenterology reports, 2015-04, Vol.17 (4), p.14-14, Article 14

2015

Volltextzugriff (PDF)

1 – 25 von 576

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(503)
Mit Volltextzugriff
(455)

Publikationsform

Artikel
(507)
Buchkapitel
(66)
Bücher
(2)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(211)
Life Sciences & Biomedicine
(203)
Gastroenterology & Hepatology
(179)
Humans
(154)
Inflammatory Bowel Disease
(123)
Ulcerative Colitis
(79)
Gastroenterology And Hepatology
(73)
Crohn's Disease
(72)
Female
(70)
Male
(68)
Adult
(64)
Gastroenterology
(61)
Middle Aged
(49)
Crohn Disease - Drug Therapy
(38)
Inflammatory Bowel Diseases - Drug Therapy
(34)
Patients
(31)
Treatment Outcome
(27)
Young Adult
(26)
Infliximab
(25)
Tumor Necrosis Factor-Alpha - Antagonists & Inhibitors
(22)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

ACG Clinical Guideline: Ulcerative Colitis in Adults

Transforming Gastroenterology Care With Telemedicine

A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease

The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium

Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis

Do inflammatory bowel disease therapies cause cancer?

Management of IBD Patients Who Are Unwilling or Unable to Receive Infusion Therapy During the COVID-19 Pandemic

Evaluating the Impact of Cost on the Treatment Algorithm for Chronic Idiopathic Constipation: Cost-Effectiveness Analysis

Are We Ready to Include Prognostic Factors in Inflammatory Bowel Disease Trials?

Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti–Tumor Necrosis Factor Therapy for Crohn’s Disease: A Meta-analysis of Placebo-controlled Trials

Medical Marijuana for Digestive Disorders: High Time to Prescribe?

Patients with IBD Want to Talk About Sleep and Treatments for Insomnia with Their Gastroenterologist

Hyperbaric oxygen therapy is well tolerated and effective for ulcerative colitis patients hospitalized for moderate-severe flares: a phase 2A pilot multi-center, randomized, double-blind, sham-controlled trial

Fostering Collaboration Through Creation of an IBD Learning Health System

Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care?

Refocusing IBD Patient Management: Personalized, Proactive, and Patient-Centered Care

Optimization of Drug Safety Profile in Inflammatory Bowel Disease Through a Personalized Approach

Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options

The Risk of Malignancy Associated with the Use of Biological Agents in Patients with Inflammatory Bowel Disease

Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population

Appropriateness of Testing for Anti–Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results

Placing Value on Telemedicine for Inflammatory Bowel Disease

People with IBD evidence more microarousals during sleep architecture assessments

Prognosticating the Course of Inflammatory Bowel Disease

Implementing Quality Measures for Inflammatory Bowel Disease

Suchergebnisse filtern